Samlyn Capital’s Abivax ABVX Stock Holding History

Samlyn Capital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-84,286	Closed	-$11.4M	–	77
2025 Q4	$11.4M	Buy	+84,286	New	+$9.2M	0.18%	70

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

Samlyn Capital's ABVX Position: Q1 2026 in Review

Samlyn Capital sold out of Abivax (ABVX) in Q1 2026, closing a stake of 84,286 shares — an estimated $11.4M sold.

Samlyn Capital first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $11.4M in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

Samlyn Capital reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
Samlyn Capital sold 84,286 Abivax shares in Q1 2026, an estimated $11.4M.
Samlyn Capital first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
Samlyn Capital's Abivax position peaked at $11.4M in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Samlyn Capital's 13F filing for Q1 2026, filed 15 May 2026.